Skip to main content
. Author manuscript; available in PMC: 2020 Jul 24.
Published in final edited form as: Exp Hematol. 2017 Oct 12;57:50–59.e6. doi: 10.1016/j.exphem.2017.09.012

Figure 3. In vitro effects of vildagliptin alone or in combination with imatinib or nilotinib on growth and survival of primary CML SCs (LSCs).

Figure 3

(A) Primary CML MNCs were incubated in control medium (Co) or in various concentrations of vildagliptin (10–10,000 nmol/L) at 37°C for 48 hours and then 3H-thymidine uptake was measured. Results are expressed as a percentage of control and represent the mean ± SD from triplicates. The dimethyl sulfoxide (DMSO) control is also shown. Patient numbers (#) refer to Supplementary Table E2 (online only, available at www.exphem.org). (B) CML MNCs were incubated in control medium (0) or in nilotinib (100–1,000 nmol/L) or vildagliptin (10 μmol/L) alone or in a combination at 37°C for 48 hours. After incubation, cells were stained with antibodies against CD34, CD45, CD38, and Annexin V to determine apoptosis in CML LSCs. DAPI was used as a viability marker to exclude nonviable cells. White bars represent medium control (0) or dimethyl sulfoxide (DMSO) control; the lined bar in grey represents cells incubated with vildagliptin alone; black bars represent cells incubated with nilotinib alone; and grey bars represent apoptosis induction after incubation with both drugs. Results are expressed as a percentage of Annexin-positive CD34+/CD38− cells and represent the mean ± SD from three independent experiments (patients #6, #7, and #8).